A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

NCT04903509 · Completed

Last updated 2026-05-28

This study tests different doses of an injectable drug called BI 1820237, alone or combined with liraglutide, in healthy men with overweight to see how well it is tolerated.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 95 people

Who can join Ages 18–50 · male only Healthy volunteers accepted.

Timeline Started 2021-06 · est. completion 2022-08

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT04903509 ↗

Description as written by the study sponsor.

The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with overweight/obesity (otherwise healthy) following subcutaneous administration of single rising doses.

Treatments tested

BI 1820237 Drug

BI 1820237
Placebo Drug

Placebo
Saxenda® also known as Liraglutide Drug

Saxenda®
Paracetamol-ratiopharm® also known as Paracetamol Drug

Paracetamol-ratiopharm®

Main thing measured	Percentage of subjects with drug-related adverse events
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04903509 ↗